Premenstrual Dysphoric Disorder

Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclical mood disorder tied to the menstrual cycle. It represents the most impairing end of the premenstrual symptom spectrum. DSM-5-TR classifies PMDD under Depressive Disorders, recognising the predominance of mood symptoms over physical complaints. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclical mood disorder tied to the menstrual cycle. It represents the most impairing end of the premenstrual symptom spectrum. DSM-5-TR classifies PMDD under Depressive Disorders, recognising the predominance of mood symptoms over physical complaints. Symptoms emerge during the luteal phase (after ovulation, roughly days 14-28 of the cycle), improve within a few days of menstrual onset, and are minimal or absent in the follicular phase (week after menses). PMDD differs from ordinary premenstrual syndrome (PMS) by its severity, its mood-predominant symptom profile, and the degree of functional impairment it causes. Anyone with ovaries can develop PMDD, including transgender individuals. ICD-11 code: GA34.41. This information is for psychoeducation only.

DSM-5-TR requires at least 5 of 11 symptoms, with at least one from the first four (mood symptoms): Core mood symptoms (must have >=1): (1) marked affective lability (mood swings, sudden sadness or tearfulness, increased sensitivity to rejection); (2) marked irritability, anger, or increased interpersonal conflicts; (3) markedly depressed mood, feelings of hopelessness, or self-deprecating thoughts; (4) marked anxiety, tension, or feeling keyed up/on edge. Additional symptoms (any combination to reach 5 total): (5) decreased interest in usual activities; (6) difficulty concentrating; (7) lethargy, fatigue, or marked lack of energy; (8) marked change in appetite, overeating, or specific food cravings; (9) hypersomnia or insomnia; (10) feeling overwhelmed or out of control; (11) physical symptoms such as breast tenderness/swelling, joint/muscle pain, bloating, or weight gain. Symptoms must be severe enough to interfere with work, school, social activities, or relationships. They must be confirmed by prospective daily ratings over at least 2 consecutive symptomatic cycles. They must not represent an exacerbation of another disorder (though they may be superimposed on one).

Proven risk factors: history of traumatic events and pre-existing anxiety disorders; cigarette smoking (current smokers: relative risk 2.1; former smokers: RR 1.8; risk increases with pack-years and is highest for women who began smoking in adolescence); obesity (linear relationship with BMI - each 1 kg/m2 increase raises risk by 3%; BMI >=35: RR 1.66 compared to BMI <20). Genetic factors: twin studies demonstrate heritable susceptibility. Variants in the gene encoding the serotonergic 5-HT1A receptor and allelic variants of the oestrogen receptor alpha gene (ESR1) are implicated. In 2017, NIH researchers

identified genetic changes that make emotional regulatory pathways more sensitive to oestrogen and progesterone in women with PMDD. Other risk factors: personal or family history of major depression or postpartum depression; history of emotional or physical abuse; high perceived stress. PMDD also increases risk for postpartum depression after pregnancy.

PMDD does not result from abnormal hormone levels. Women with PMDD have the same circulating concentrations of oestradiol, progesterone, and allopregnanolone as unaffected women. The difference lies in an abnormal central nervous system sensitivity to normal cyclical fluctuations of these hormones. Serotonin plays a central role. Three lines of evidence support this: (1) SSRIs rapidly and effectively reduce PMDD symptoms, often within 1-2 cycles; (2) depleting serotonin (via tryptophan-free diet) or blocking serotonin receptors triggers PMDD-like symptoms; (3) women with PMDD have lower serotonin transporter density and abnormal serotonergic responsiveness across cycle phases. Progesterone's neuroactive metabolite allopregnanolone modulates GABA-A receptors. Women with PMDD may have diminished GABA-A receptor sensitivity to allopregnanolone, disrupting the normal anxiolytic and calming effects of this neurosteroid during the luteal phase. Suppressing ovulation with GnRH agonists eliminates symptoms; re-exposure to oestrogen or progesterone (even at stable doses) can re-trigger them, confirming that CNS sensitivity to hormonal change - not hormone levels themselves - drives the disorder. Glutamate levels fluctuate cyclically in all women, but women with PMDD show heightened sensitivity to these changes. HPA axis abnormalities are present: lower cortisol and beta-endorphin levels during both follicular and luteal phases suggest dysregulation similar to that seen in mood disorders.

Approximately 70-90% of menstruating women report some premenstrual discomfort. About 20-30% experience symptoms severe enough to qualify as PMS. PMDD, the most severe form, affects 3-8% of menstruating women. Taking into account average cycle counts (~459 cycles across childbearing years) and an average of 6.4 days of severe symptoms per cycle, a woman with PMDD experiences approximately 8 cumulative years of debilitating symptoms across her reproductive lifespan. PMDD occurs across all cultures, races, and socioeconomic groups. It affects women from menarche through menopause. Symptoms typically worsen with age and may be most severe in the late 30s and 40s. PMDD resolves after menopause (natural or surgical) and is absent during pregnancy and amenorrhoea.

The core pathophysiology centres on aberrant CNS response to normal ovarian steroid fluctuations, particularly during the luteal-to-follicular transition.

Serotonin: women with PMDD show phase-dependent serotonergic changes. They have higher serotonergic responsiveness in the follicular phase than the luteal phase, the opposite of what is seen in unaffected women. Serotonin transporter receptor density is lower in PMDD. SSRIs work in PMDD partly by modulating enzymes involved in creating progesterone metabolites that interact with GABA-A receptors, linking serotonergic and GABAergic systems. GABA: progesterone metabolites (especially allopregnanolone) potentiate GABA-A receptor-mediated inhibition. In PMDD, the GABA-A receptor complex shows diminished functional sensitivity. Imaging studies show cyclical changes in GABA levels across the menstrual cycle in all women, but symptomatic women respond abnormally. Glutamate: cyclical fluctuations occur in all women, but women with PMDD show increased sensitivity to these shifts, potentially contributing to anxiety and tension. Neurosteroids: allopregnanolone levels drop during the late luteal phase, and this withdrawal may trigger symptoms in sensitised women - analogous to a benzodiazepine withdrawal effect. HPA axis: reduced cortisol and beta-endorphin in both phases point to tonic HPA dysregulation.

A thorough history targets the temporal relationship between symptoms and menstrual cycle phases. The hallmark pattern: symptoms appear in the luteal phase, peak in the days before menses, and resolve within 1-4 days of menstrual flow. A symptom-free interval in the follicular phase is essential for diagnosis - if symptoms persist throughout the cycle, another disorder is more likely. Three domains of PMDD symptoms to assess: (1) Mood - sadness, hopelessness, mood swings, tearfulness, irritability, anger, anxiety, feeling on edge; (2) Cognitive/behavioural - difficulty concentrating, decreased interest, lethargy, feeling out of control, changes in appetite and sleep; (3) Physical - breast tenderness, bloating, joint/muscle pain, headache, weight gain. Physical examination: generally normal. Rule out thyroid disease (TSH), anaemia (CBC), and perimenopause (FSH, oestradiol if age-appropriate). Pelvic exam if endometriosis or other gynaecological conditions are suspected. No specific lab test confirms PMDD.

DSM-5-TR criteria require: (A) at least 5 of 11 symptoms, including at least 1 mood symptom, present in most menstrual cycles during the past year; (B) symptoms severe enough to impair functioning; (C) symptoms not merely an exacerbation of another disorder; (D) pattern confirmed by prospective daily ratings for at least 2 consecutive symptomatic cycles. Prospective daily charting is mandatory. Retrospective recall alone is unreliable and tends to overestimate severity. Validated charting tools include the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST). A provisional diagnosis can be made before 2 cycles of charting are completed. ICD-11 (GA34.41) classifies PMDD under Diseases of the Genitourinary System rather than under mental disorders, reflecting a different conceptual framework.

Daily symptom charting for at least 2 consecutive cycles is the gold standard. Validated instruments: Daily Record of Severity of Problems (DRSP), Premenstrual Symptoms Screening Tool (PSST), Calendar of Premenstrual Experiences (COPE), Visual Analogue Scales. Screen for comorbidities: major depressive disorder, generalised anxiety disorder, bipolar disorder, borderline personality disorder, thyroid disease. A menstrual diary or cycle-tracking app can help correlate symptoms with cycle phases. Laboratory workup to exclude medical mimics: TSH (thyroid), CBC (anaemia), prolactin (if galactorrhoea), FSH/oestradiol (perimenopause in women over 40). Blood sugar if energy/appetite changes are prominent. These labs are to exclude alternative diagnoses, not to confirm PMDD.

Premenstrual syndrome (PMS): milder symptoms, primarily physical; does not require mood symptoms or significant functional impairment. PMDD represents the severe end of the PMS spectrum. Major depressive disorder/dysthymia: persistent symptoms throughout the cycle, not limited to the luteal phase. PMDD requires a symptom-free follicular phase. Bipolar disorder: mood episodes last weeks to months, not days; mania/hypomania is absent in PMDD. Generalised anxiety disorder: chronic anxiety unrelated to menstrual cycle timing. Borderline personality disorder: chronic emotional instability and interpersonal difficulties, not cyclically linked to menses. Thyroid disorders: hypothyroidism causes fatigue, mood changes, weight gain; check TSH. Perimenopause: irregular cycles, vasomotor symptoms; hormonal fluctuations may trigger or worsen mood symptoms. Endometriosis/gynaecological conditions: pelvic pain and physical symptoms may overlap; pelvic exam and imaging differentiate.

Premenstrual exacerbation of another disorder: if a pre-existing mood or anxiety disorder worsens premenstrually but symptoms never fully remit, this is premenstrual exacerbation, not PMDD.

Treatment of Premenstrual Dysphoric Disorder (PMDD) targets the cyclical mood, behavioural, and physical symptoms that occur in the luteal phase. Pharmacotherapy: SSRIs are the first-line treatment and are effective for both continuous and luteal-phase-only dosing. Sertraline (50-150 mg), fluoxetine (20 mg), and escitalopram (10-20 mg) have the strongest evidence. Response rates are approximately 60-70%. Luteal-phase dosing (starting the SSRI at ovulation and discontinuing at menses onset) is effective and may be preferred by patients who do not wish to take medication continuously. Response is often rapid, within 1-2 cycles, unlike the 4-6 week lag in major depression. SNRIs (venlafaxine 75-150 mg) are an alternative. Hormonal treatments: combined oral contraceptives containing drospirenone (e.g. Yaz, 20 mcg ethinyl oestradiol / 3 mg drospirenone in a 24/4 regimen) reduce PMDD symptoms. GnRH agonists (leuprolide, goserelin) with add-back hormone therapy suppress ovulation and effectively eliminate symptoms but are reserved for severe, refractory cases due to bone density concerns. Continuous oral contraceptive use to eliminate cycling can help. For severe, refractory PMDD, bilateral oophorectomy with hormone replacement therapy is a last-resort option that definitively eliminates symptoms. Non-Pharmacological Approaches: CBT adapted for PMDD addresses cognitive distortions about premenstrual experiences, stress management, and coping skills training. Regular aerobic exercise (at least 30 minutes, 3-5 times/week) provides modest symptom relief. Calcium supplementation (1200 mg/day) has RCT evidence supporting benefit. Vitamin B6 (50-100 mg/day) and magnesium may provide modest relief. Lifestyle Modifications: regular exercise, adequate sleep (7-9 hours), balanced diet with reduced caffeine, alcohol, and sodium during the luteal phase, and stress management techniques support symptom reduction. Symptom tracking helps patients anticipate and prepare for symptomatic periods.

PMDD is a chronic, cyclical condition that persists throughout the reproductive years. Symptoms often worsen during perimenopause due to greater hormonal instability. PMDD resolves definitively after menopause. With SSRI treatment, 60-70% of women experience significant symptom reduction. Luteal-phase dosing offers an effective option with reduced medication exposure. Women who do not respond to SSRIs may respond to hormonal interventions. About 15-20% of cases prove refractory to first-line treatments and require combination approaches or GnRH agonists. Untreated PMDD substantially impairs quality of life, work productivity, and interpersonal relationships over years. PMDD increases risk for postpartum depression. Women with PMDD should be monitored closely during pregnancy and the postpartum period. Suicidal ideation during the luteal phase occurs in a significant minority and warrants routine screening.

Untreated PMDD causes recurring, predictable impairment across multiple life domains. Occupational: lost work productivity, estimated at several work days per month; increased absenteeism and healthcare utilisation. Interpersonal: cyclical irritability and anger cause relationship strain; partners and children are affected. Suicidality: PMDD significantly increases risk of suicidal ideation and suicide attempts, particularly in the late luteal phase. Comorbid depression: women with PMDD have elevated lifetime risk of major depressive disorder and postpartum depression. Substance use: some women self-medicate with alcohol or other substances during symptomatic periods. Physical health: chronic sleep disruption, overeating, and reduced exercise during symptomatic phases contribute to weight gain and metabolic consequences over time.

No primary prevention for PMDD exists, as susceptibility is largely genetic. Risk reduction: avoiding smoking (especially in adolescence), maintaining healthy weight (BMI <25), and regular exercise may reduce severity. Key education points: PMDD is a real, biologically-based condition - not 'just PMS' or emotional weakness. The brain's response to normal hormonal changes drives it, not abnormal hormone levels. Effective treatments exist - SSRIs work rapidly and can be taken only during the symptomatic phase. Tracking symptoms daily is essential for diagnosis and treatment monitoring. Symptoms should be validated by partners, family members, and employers. Planning demanding tasks during the follicular phase can reduce functional impact. Suicidal thoughts during the luteal phase are a medical symptom and require immediate clinical attention. Support organisations like the International Association for Premenstrual Disorders (IAPMD) provide peer support and educational resources.

Premenstrual symptoms have been recognised for centuries, with descriptions of 'menses moodiness' in 18th-century medical texts. 1931: Robert Frank coined 'premenstrual tension' to describe cyclical emotional symptoms. 1953: Katharina Dalton and Raymond Greene introduced 'premenstrual syndrome' as a broader clinical entity. 1987: DSM-III-R included Late Luteal Phase Dysphoric Disorder (LLDD) in the appendix as a condition requiring further study - this was controversial, with feminist critics arguing it pathologised normal female biology. 1994: DSM-IV renamed it Premenstrual Dysphoric Disorder and kept it in the appendix. 2013: DSM-5 elevated PMDD to a full diagnostic category under Depressive Disorders, reflecting accumulated evidence of its distinct neurobiology, treatment response, and functional impact. ICD-11 classifies it under gynaecological conditions (GA34.41) rather than mental disorders.

PMDD exists at the intersection of psychiatry, gynaecology, and gender politics. Critics argue that classifying cyclical mood changes as a mental disorder pathologises normal female reproductive biology and could be used to undermine women's credibility. Proponents counter that withholding a diagnosis denies suffering women access to effective treatment and insurance coverage. Stigma operates on multiple levels. Many women with PMDD report that their symptoms are dismissed as 'just PMS' by healthcare providers, family, and employers. Average time to diagnosis is approximately 12 years. Cultural attitudes

about menstruation (taboo, shame, 'hysteria' narratives) compound the problem. In some workplaces, acknowledging premenstrual symptoms carries professional risk. PMDD affects women across all cultures, but awareness, diagnosis, and treatment access vary enormously. Low- and middle-income countries have minimal recognition of PMDD as a clinical entity. Even in high-income countries, many primary care providers are unfamiliar with the distinction between PMS and PMDD.

Active research areas: genetic studies identifying specific variants conferring susceptibility to hormonal sensitivity; neuroimaging of serotonergic and GABAergic circuit changes across the menstrual cycle. Novel pharmacological targets: selective progesterone receptor modulators (ulipristal acetate); GABA-A receptor modulators (sepranolone/UC1010, a GABA-A modulating steroid antagonist, has shown promise in phase II trials for blocking allopregnanolone's effects). Digital health: cycle-tracking apps with integrated symptom monitoring for prospective diagnosis. Biomarkers: peripheral allopregnanolone sensitivity assays; serotonin transporter imaging. Neuromodulation: transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are being explored. RCTs evaluating combined SSRI plus hormonal strategies for refractory cases are ongoing.

APA. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR). APA Publishing. Sadock BJ, Sadock VA, Ruiz P. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls [Internet]. Premenstrual Dysphoric Disorder. NCBI Bookshelf. StatPearls Publishing. WHO. (2022). ICD-11 for Mortality and Morbidity Statistics. Geneva: World Health Organization.

NIMH: https://www.nimh.nih.gov StatPearls - Premenstrual Syndrome and Premenstrual Dysphoric Disorder: https://www.ncbi.nlm.nih.gov/books/NBK532307/ WHO ICD-11: https://icd.who.int International Association for Premenstrual Disorders (IAPMD): https://iapmd.org MGH Center for Women's Mental Health: https://womensmentalhealth.org Crisis: 988 (US Suicide & Crisis Lifeline); Text HOME to 741741 (Crisis Text Line)